Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

HDDO-1801 Intervention Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04097951
Recruitment Status : Not yet recruiting
First Posted : September 20, 2019
Last Update Posted : September 20, 2019
Sponsor:
Information provided by (Responsible Party):
Hyundai Pharmaceutical Co., LTD.

Brief Summary:
A randomized, open-label, single-dose, 3-period, 6-sequence, 3-way crossover study

Condition or disease Intervention/treatment Phase
Respiratory Disease Drug: Combinations Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Randomized, Open-label, Single-dose Study to Evaluate the Safety and the Pharmacokinetics After Oral Concurrent Administration of HDDO-18011 and HDDO-18012 in Healthy Adult Subjects
Estimated Study Start Date : November 8, 2019
Estimated Primary Completion Date : January 8, 2020
Estimated Study Completion Date : February 28, 2020

Arm Intervention/treatment
Experimental: Montelukast Drug: Combinations
Montelukast and Bepotastine Combination

Experimental: Bepotastine Drug: Combinations
Montelukast and Bepotastine Combination

Experimental: Montelukast + Bepotastine Drug: Combinations
Montelukast and Bepotastine Combination




Primary Outcome Measures :
  1. Pharmacokinetic Assessment [ Time Frame: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24hours ]
    Montelukast and Bepotastine Maximum Plasma Concentration

  2. Pharmacokinetic Assessment [ Time Frame: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24hours ]
    Montelukast and Bepotastine Area under Curve from time zero to the last quantifiable concentration


Secondary Outcome Measures :
  1. Pharmacokinetic Assessment [ Time Frame: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24hours ]
    Montelukast and Bepotastine Area under Curve from time zero to infinity

  2. Pharmacokinetic Assessment [ Time Frame: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24hours ]
    Montelukast and Bepotastine time to maximum plasma concentration

  3. Pharmacokinetic Assessment [ Time Frame: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24hours ]
    Montelukast and Bepotastine half time



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy adult male aged 19 years and younger than 50 years old at the time of the screening
  2. Those who weigh more than 50 kg and whose calculated BMI is within the 18.0-29.0 kg/m2 range BMI = (weight [kg])/(key [m])2
  3. A person who is judged to be suitable for a test through physical examination and examination according to this test plan. That is, a person who has no congenital or chronic diseases and who has not had any pathological symptoms or findings within the last 3 years
  4. A person who is judged to be suitable for a test in accordance with this test plan (if the results of a clinical laboratory test are within or outside the reference value of the hospital affiliated with Inha University Medical Center, the tester determines that there is no clinical significance)
  5. After hearing the detailed description of this clinical trial and fully understanding it, the person who agrees in writing to decide his/her participation and to comply with the precautions

Exclusion Criteria:

  1. Persons with clinical significant cardiovascular, respiratory, liver, kidney, nervous system, endocrine, blood and tumor, mental illness, and urinary tract
  2. Persons with gastrointestinal relationship diseases (such as gastrointestinal ulcers, gastritis, gastrointestinal tract diseases, Crohn's disease, etc.) that may affect the absorption of clinical trial medications, and persons with past history of gastrointestinal relationship surgery (except for simple appendectomy or hernia surgery)
  3. Those with genetic problems such as galactose intolerance, Lapp lactase deficient or glucose-galactose malabsorption
  4. A person with a history of hypersensitivity or clinically significant hypersensitivity to a drug or other drug (aspirin, antibiotics, etc.) that contains the components of Montelukast and the components of Bepotastine or the same family.
  5. A person who showed a clinically significant low blood pressure (hydraulic < 90mmHg) or high blood pressure (hydraulic ≥ 150mmHg or dilatant blood pressure ≥ 95mmHg) during the screening test
  6. One of the following results is displayed in a screening test:

    • AST or ALT > Double the normal range limit
    • Total bilirubin > 2.0 mg/dL
    • Ratios of sand dune (eGFR) < 60mL/min/1.73m2
  7. Drinking continuously (21 units/week exceeded, 1 unit = 10 g = 12.5 mL of pure alcohol) or who cannot abstain from drinking during clinical trials
  8. Those who smoke continuously (more than 10 days) or who cannot quit smoking during the clinical trial period.
  9. Those who participated in other clinical or biological equivalence tests within six months prior to the date of the first medication (the last day of the medication for clinical or biological equivalence tests)
  10. A person who donated all blood within 60 days prior to the date of the first medication, or who donated the ingredients within 30 days, or who received the blood within 30 days.
  11. Those who have taken any prescription or herbal medicine within 14 days prior to the date of the first dose or who have taken any general medication (OTC) within 7 days (however, they may participate in a clinical trial if other conditions are reasonable according to the judgment of the tester.)
  12. A person who has taken a medication that induces and inhibits the drug metabolic enzyme, such as barbital drugs, within one month before the start of the test
  13. mentally ill and drug addicts
  14. A person who has been on a diet (especially grapefruit juice or its products) that can affect the absorption, distribution, metabolism, and excretion of a drug within seven days prior to the date of the first dose.
  15. Those who do not agree to exclude the possibility of pregnancy using the medically recognized contraceptives* from the date of the first administration of the clinical trial drug to the date of the last clinical trial medication.

    *Medically accepted contraceptives: intrauterine devices, vascular surgery, intubation and block contraception (male condoms, female condoms, cervical caps, contraceptives, sponges, etc.) or when using a combination of two or more blockage methods.

  16. Those who are unwilling or unable to comply with diet and lifestyle guidelines required for clinical testing;
  17. Other clinical laboratory tests found that the tester is unfit to participate in a clinical trial due to clinical abnormalities or other reasons (e.g., non-compliance with instructions, non-cooperative attitude, etc.)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04097951


Contacts
Layout table for location contacts
Contact: Son Su Min 82-2-2600-7628 smson@myhdpharm.com

Locations
Layout table for location information
Korea, Republic of
Inha University Hospital Completed
Junggu, Incheon, Korea, Republic of, 22332
Sponsors and Collaborators
Hyundai Pharmaceutical Co., LTD.
Investigators
Layout table for investigator information
Principal Investigator: Cho Sang Heon Inha University Hospital

Layout table for additonal information
Responsible Party: Hyundai Pharmaceutical Co., LTD.
ClinicalTrials.gov Identifier: NCT04097951     History of Changes
Other Study ID Numbers: HT-012-01
First Posted: September 20, 2019    Key Record Dates
Last Update Posted: September 20, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiration Disorders
Respiratory Tract Diseases
Bepotastine besilate
Montelukast
Anti-Asthmatic Agents
Respiratory System Agents
Leukotriene Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP1A2 Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action
Anti-Allergic Agents